We've noticed that all of these transformation activities– care transformation, quality improvement, are all actually working, explained Kavita Patel, MD, MS, non-resident senior fellow at the Brookings Institution.
We've noticed that all of these transformation activities— care transformation, quality improvement, are all actually working, explained Kavita Patel, MD, MS, non-resident senior fellow at the Brookings Institution.
Transcript:
How has the Oncology Care Model (OCM) evolved? What do you think it does well, and what are some of the pain points that participanting practices continue to face?
So, the OCM has evolved in a couple of interesting ways. Data is now a very regular, kind of term with the OCM practices. Almost all of them have done something with the access to claims data that they have, so that’s actually progress.
The second thing that they’ve all noticed is that these transformation activities— care transformation, quality improvement, are all actually working. Not necessarily the way they might have thought, but they’re making patients feel like they’re getting better care and, in some cases, they’re delivering on improvements in quality measures.
The thing that’s not working as well is still this kind of clunkiness with things like attribution. It takes a long time— there’s a lag in how CMS processes the data about attribution and what we call reconciliation. It might take doctors up to [about] 18 months to ultimately know if the patient they thought they were taking care of is actually acknowledged by Medicare as their patient, and then vice versa. People that they thought were their patients are not necessarily theirs and they don’t find out until about a year later. So, there’s still some clunky things that have to do with how Medicare just processes claims under the model.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More